Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Carbapenem Antibiotic | Research

The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019

Authors: Marya D. Zilberberg, Brian H. Nathanson, Laura A. Puzniak, Ryan J. Dillon, Andrew F. Shorr

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Inappropriate empiric antimicrobial treatment (IET) contributes to worsened outcomes. While IET’s differential impact across types of nosocomial pneumonia (NP: non-ventilated [nvHABP], ventilated [vHABP] hospital-acquired and ventilator-associated [VABP] bacterial pneumonia) is established, its potential interaction with the bacterial etiology is less clear.

Methods

We conducted a multicenter retrospective cohort study in the Premier Healthcare Database using an administrative algorithm to identify NP. We paired respective pathogens with empiric treatments. Antimicrobial coverage was appropriate if a drug administered within 2 days of infection onset covered the recovered organism(s). All other treatment was IET.

Results

Among 17,819 patients with NP, 26.5% had nvHABP, 25.6% vHABP, and 47.9% VABP. Gram-negative (GN) organisms accounted for > 50% of all infections. GN pathogens were ~ 2 × as likely (7.4% vHABP to 10.7% nvHABP) to engender IET than Gram-positive (GP, 2.9% vHABP to 4.9% nvHABP) pathogens. Although rare (5.6% nvHABP to 8.3% VABP), GN + GP infections had the highest rates of IET (6.7% vHABP to 12.9% nvHABP). Carbapenem-resistant GNs were highly likely to receive IET (33.8% nvHABP to 40.2% VABP). Hospital mortality trended higher in the IET group, reaching statistical significance in GN + GP vHABP (47.8% IET vs. 29.3% non-IET, p = 0.016). 30-day readmission was more common with IET (16.0%) than non-IET (12.6%, p = 0.024) in GN VABP. Generally post-infection onset hospital length of stay and costs were higher with IET than non-IET.

Conclusions

IET is ~ 2 × more common in GN than GP infections. Although the magnitude of its impact varies by NP type, IET contributes to worsened clinical and economic outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of adults with hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.CrossRef Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of adults with hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.CrossRef
2.
go back to reference Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208.CrossRef Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208.CrossRef
3.
go back to reference Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A. Nosocomial pneumonia in the Intensive Care Unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182:1533–9.CrossRef Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A. Nosocomial pneumonia in the Intensive Care Unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182:1533–9.CrossRef
4.
go back to reference Vallecoccia MS, Dominedo C, Cutuli SL, Martin-Loeches I, Torres A, De Pascale G. Is ventilated hospital-acquired pneumonia a worse entity then ventilator-associated pneumonia? Eur Resp Rev. 2020;29: 200023.CrossRef Vallecoccia MS, Dominedo C, Cutuli SL, Martin-Loeches I, Torres A, De Pascale G. Is ventilated hospital-acquired pneumonia a worse entity then ventilator-associated pneumonia? Eur Resp Rev. 2020;29: 200023.CrossRef
5.
go back to reference Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Descriptive epidemiology and outcomes of non-ventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the US, 2012–2019. Crit Care Med. 2022;50:460–8.PubMed Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Descriptive epidemiology and outcomes of non-ventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the US, 2012–2019. Crit Care Med. 2022;50:460–8.PubMed
6.
go back to reference Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014–2019. Infect Control Hosp Epidemiol. 2022;43:277–83.CrossRef Zilberberg MD, Nathanson BH, Puzniak LA, Shorr AF. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014–2019. Infect Control Hosp Epidemiol. 2022;43:277–83.CrossRef
7.
go back to reference Zilberberg MD, Nathanson BH, Puzniak LA, Zilberberg NWD, Shorr AF. Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: a cohort study, United States, 2014–2019. Crit Care Explor. 2022;4: e0667.CrossRef Zilberberg MD, Nathanson BH, Puzniak LA, Zilberberg NWD, Shorr AF. Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: a cohort study, United States, 2014–2019. Crit Care Explor. 2022;4: e0667.CrossRef
8.
go back to reference Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.CrossRef Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.CrossRef
10.
go back to reference Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155:1119–30.CrossRef Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155:1119–30.CrossRef
11.
go back to reference Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections. Infect Control Hosp Epidemiol. 2018;39:1112–4.CrossRef Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections. Infect Control Hosp Epidemiol. 2018;39:1112–4.CrossRef
13.
go back to reference Rothberg MB, Pekow PS, Priya A, Zilberberg MD, Belforti R, Skiest D, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS ONE. 2014;9(1): e87382.CrossRef Rothberg MB, Pekow PS, Priya A, Zilberberg MD, Belforti R, Skiest D, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS ONE. 2014;9(1): e87382.CrossRef
14.
go back to reference Rothberg MB, Haessler S, Lagu T, Lindenauer PK, Pekow PS, Priya A, et al. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S107–15.CrossRef Rothberg MB, Haessler S, Lagu T, Lindenauer PK, Pekow PS, Priya A, et al. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S107–15.CrossRef
15.
go back to reference Haessler S, Lindenauer PK, Zilberberg MD, Imrey PB, Yu PC, Higgins T, Deshpande A, Rothberg MB. Blood cultures versus respiratory cultures: 2 different views of pneumonia. Clin Infect Dis. 2020;71:1604–12.CrossRef Haessler S, Lindenauer PK, Zilberberg MD, Imrey PB, Yu PC, Higgins T, Deshpande A, Rothberg MB. Blood cultures versus respiratory cultures: 2 different views of pneumonia. Clin Infect Dis. 2020;71:1604–12.CrossRef
16.
go back to reference Alvarez-Lerma F, ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22(5):387–94.CrossRef Alvarez-Lerma F, ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22(5):387–94.CrossRef
17.
go back to reference Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–8.CrossRef Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–8.CrossRef
18.
go back to reference Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851–63.CrossRef Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851–63.CrossRef
19.
go back to reference Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, Teixeira PJ. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10:R125.CrossRef Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, Teixeira PJ. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10:R125.CrossRef
20.
go back to reference Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanese J, Martin C. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007;35:379–85.CrossRef Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, Albanese J, Martin C. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007;35:379–85.CrossRef
21.
go back to reference Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. incidence and outcomes of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.CrossRef Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. incidence and outcomes of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63.CrossRef
22.
go back to reference Ko RE, Min KH, Hong SB, et al. Characteristics, management, and clinical outcomes of patients with hospital acquired and ventilator-associated pneumonia: a multicenter cohort study in Korea. Tuberc Respir Dis. 2021;84:317–25.CrossRef Ko RE, Min KH, Hong SB, et al. Characteristics, management, and clinical outcomes of patients with hospital acquired and ventilator-associated pneumonia: a multicenter cohort study in Korea. Tuberc Respir Dis. 2021;84:317–25.CrossRef
Metadata
Title
The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
Authors
Marya D. Zilberberg
Brian H. Nathanson
Laura A. Puzniak
Ryan J. Dillon
Andrew F. Shorr
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07755-y

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.